May 20th, 2022 · Common Contracts · 1000 similar Biofrontera Inc. – BIOFRONTERA INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 16, 2022, between Biofrontera Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
This Securities Purchase Agreement (this “Agreement”) is dated as of May 16, 2022, between Biofrontera Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
May 20th, 2022 · Common Contracts · 1000 similar Tenax Therapeutics, Inc. – REGISTRATION RIGHTS AGREEMENT This Agreement is made pursuant to the Securities Purchase Agreement for Units, dated as of the date hereof, between the Company and the Purchaser (the “Purchase Agreement”).
This Agreement is made pursuant to the Securities Purchase Agreement for Units, dated as of the date hereof, between the Company and the Purchaser (the “Purchase Agreement”).
October 12th, 2021 · Common Contracts · 1000 similar Xenetic Biosciences, Inc. – Xenetic Biosciences, Inc. and Trustee INDENTURE Dated as of _________, ___ Providing for Issuance of Senior Debt Securities in Series INDENTURE THIS INDENTURE between Xenetic Biosciences, Inc., a Nevada corporation (hereinafter called the “Company”) having its principal office at 99 Hayden Ave, Suite 230, Lexington, Massachusetts 02421, and, as trustee (hereinafter called the “Trustee”), is made and entered into as of ____________, ___.
THIS INDENTURE between Xenetic Biosciences, Inc., a Nevada corporation (hereinafter called the “Company”) having its principal office at 99 Hayden Ave, Suite 230, Lexington, Massachusetts 02421, and, as trustee (hereinafter called the “Trustee”), is made and entered into as of ____________, ___.
March 25th, 2020 · Common Contracts · 1000 similar Evofem Biosciences, Inc. – RIGHTS AGREEMENT RIGHTS AGREEMENT, dated as of March 24, 2020 (the “Agreement”), between Evofem Biosciences, Inc., a Delaware corporation (the “Company”), and Philadelphia Stock Transfer, Inc., as rights agent (the “Rights Agent”). WHEREAS, effective...
January 19th, 2022 · Common Contracts · 1000 similar Vincerx Pharma, Inc. – VINCERX PHARMA, INC. TO Trustee Indenture Dated as of , 20
August 3rd, 2021 · Common Contracts · 1000 similar Healthcare Royalty, Inc. – CREDIT AGREEMENT dated as of August [ ● ], 2021 among HCRX INVESTMENTS HOLDCO, L.P., as the Borrower, HCRX INTERMEDIATE HOLDCO, L.P., as Holdings, THE LENDERS FROM TIME TO TIME PARTY HERETO, and CITIBANK, N.A., as Administrative Agent CITIBANK, N.A.,... This Credit Agreement (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, this “Agreement”), dated as of August [ n ], 2021, among HCRX Investments Holdco, L.P., a Delaware limited partnership (the “Borrower”), HCRX Intermediate Holdco, L.P. a Delaware limited partnership (“Holdings”), each lender and L/C Issuer (as defined below) from time to time party hereto (collectively, the “Lenders” and, individually, a “Lender”) and CITIBANK, N.A., as administrative agent (the “Administrative Agent”) and each L/C Issuer (as defined below).
This Credit Agreement (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, this “Agreement”), dated as of August [ n ], 2021, among HCRX Investments Holdco, L.P., a Delaware limited partnership (the “Borrower”), HCRX Intermediate Holdco, L.P. a Delaware limited partnership (“Holdings”), each lender and L/C Issuer (as defined below) from time to time party hereto (collectively, the “Lenders” and, individually, a “Lender”) and CITIBANK, N.A., as administrative agent (the “Administrative Agent”) and each L/C Issuer (as defined below).
February 16th, 2021 · Common Contracts · 1000 similar 4D Pharma PLC – WARRANT AGREEMENT This Warrant Agreement (this “Agreement”) is made as of August 28, 2018 between Longevity Acquisition Corporation, a British Virgin Islands company, with offices at Suite 906, Tower W1, Oriental Plaza, No. 1 East Chang’an Street, Dongcheng District, Beijing, People’s Republic of China (“Company”), and Continental Stock Transfer & Trust Company, a New York corporation, with offices at One State Street, 30th Floor, New York, New York 10004 (“Warrant Agent”).
This Warrant Agreement (this “Agreement”) is made as of August 28, 2018 between Longevity Acquisition Corporation, a British Virgin Islands company, with offices at Suite 906, Tower W1, Oriental Plaza, No. 1 East Chang’an Street, Dongcheng District, Beijing, People’s Republic of China (“Company”), and Continental Stock Transfer & Trust Company, a New York corporation, with offices at One State Street, 30th Floor, New York, New York 10004 (“Warrant Agent”).
October 12th, 2021 · Common Contracts · 990 similar RespireRx Pharmaceuticals Inc. – SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of October 7, 2021, by and between RESPIRERX PHARMACEUTICALS INC., a Delaware corporation, with headquarters located at 126 Valley Road, Suite C, Glen Rock, NJ 07452 (the “Company”), and DARIUSZ NASIEK and SARA NASIEK JTTEN, with an address at [***] (the “Buyer”).
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of October 7, 2021, by and between RESPIRERX PHARMACEUTICALS INC., a Delaware corporation, with headquarters located at 126 Valley Road, Suite C, Glen Rock, NJ 07452 (the “Company”), and DARIUSZ NASIEK and SARA NASIEK JTTEN, with an address at [***] (the “Buyer”).
June 17th, 2020 · Common Contracts · 990 similar Mylan N.V. – AMENDMENT NO. 2 TO REVOLVING CREDIT AGREEMENT This REVOLVING CREDIT AGREEMENT (this “Agreement”) is dated as of July 27, 2018 among MYLAN INC., a Pennsylvania corporation (the “Borrower”), MYLAN N.V., a public limited liability company (naamloze vennootschap) incorporated and existing under the laws of the Netherlands, with its corporate seat (statutaire zetel) in Amsterdam, the Netherlands and registered with the Dutch chamber of commerce under number 61036137 (the “Parent” and a “Guarantor”), certain Affiliates and Subsidiaries of the Parent from time to time party hereto as Guarantors, each Lender and Issuing Bank from time to time party hereto, and BANK OF AMERICA, N.A., as Administrative Agent.
This REVOLVING CREDIT AGREEMENT (this “Agreement”) is dated as of July 27, 2018 among MYLAN INC., a Pennsylvania corporation (the “Borrower”), MYLAN N.V., a public limited liability company (naamloze vennootschap) incorporated and existing under the laws of the Netherlands, with its corporate seat (statutaire zetel) in Amsterdam, the Netherlands and registered with the Dutch chamber of commerce under number 61036137 (the “Parent” and a “Guarantor”), certain Affiliates and Subsidiaries of the Parent from time to time party hereto as Guarantors, each Lender and Issuing Bank from time to time party hereto, and BANK OF AMERICA, N.A., as Administrative Agent.
April 20th, 2022 · Common Contracts · 925 similar Deutsche Bank Trust Co Americas/ ADR Group – DEPOSIT AGREEMENT DEPOSIT AGREEMENT, dated as of [●], 2022, by and among (i) Belite Bio, Inc, a company incorporated in the Cayman Islands, with its principal executive office at 5820 Oberlin Drive, Suite 101, San Diego, CA 92121, United States of America and its registered office at Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman
DEPOSIT AGREEMENT, dated as of [●], 2022, by and among (i) Belite Bio, Inc, a company incorporated in the Cayman Islands, with its principal executive office at 5820 Oberlin Drive, Suite 101, San Diego, CA 92121, United States of America and its registered office at Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman
April 7th, 2022 · Common Contracts · 914 similar Selecta Biosciences Inc – SELECTA BIOSCIENCES, INC. (a Delaware corporation) 27,428,572 Shares of Common Stock and Warrants to Purchase 20,571,429 Shares of Common Stock UNDERWRITING AGREEMENT
September 27th, 2011 · Common Contracts · 846 similar Biozone Pharmaceuticals, Inc. – REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (the “Agreement”) dated as of the 22nd day of September, 2011, is entered into by and between BIOZONE PHARMACEUTICALS, INC., a Nevada corporation (the “Company”), and the Purchaser signatory to that certain Purchase Agreement (the “Investor” ) dated the date hereof by and between the Company and the Investors (the “Purchase Agreement”). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.
This Registration Rights Agreement (the “Agreement”) dated as of the 22nd day of September, 2011, is entered into by and between BIOZONE PHARMACEUTICALS, INC., a Nevada corporation (the “Company”), and the Purchaser signatory to that certain Purchase Agreement (the “Investor” ) dated the date hereof by and between the Company and the Investors (the “Purchase Agreement”). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.
May 24th, 2022 · Common Contracts · 791 similar Advaxis, Inc. – UNDERWRITING AGREEMENT between ADVAXIS, INC. and as Representative of the Several Underwriters As Representative of the several Underwriters named on Schedule 1 attached hereto 590 Madison Avenue, 28th Floor New York, New York 10022
As Representative of the several Underwriters named on Schedule 1 attached hereto 590 Madison Avenue, 28th Floor New York, New York 10022
May 24th, 2017 · Common Contracts · 786 similar Kindred Biosciences, Inc. – KINDRED BIOSCIENCES, INC. AND AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC, as Rights Agent RIGHTS AGREEMENT dated as of May 19, 2017
May 12th, 2022 · Common Contracts · 686 similar Oramed Pharmaceuticals Inc. – INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of August 30, 2016 between Oramed Pharmaceuticals Inc., a Delaware corporation (the “Company”), and Kevin Rakin (“Indemnitee”).
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of August 30, 2016 between Oramed Pharmaceuticals Inc., a Delaware corporation (the “Company”), and Kevin Rakin (“Indemnitee”).
August 29th, 2019 · Common Contracts · 681 similar Therapix Biosciences Ltd. – THERAPIX BIOSCIENCES LTD. AND THE BANK OF NEW YORK MELLON As Depositary AND OWNERS AND HOLDERS OF AMERICAN DEPOSITARY SHARES Amended and Restated Deposit Agreement Dated as of March 21, 2017 AMENDED AND RESTATED DEPOSIT AGREEMENT AMENDED AND RESTATED DEPOSIT AGREEMENT dated as of March 21, 2017, among THERAPIX BIOSCIENCES LTD., a company incorporated under the laws of the State of Israel (herein called the Company), THE BANK OF NEW YORK MELLON, a New York banking corporation (herein called the Depositary), and all Owners and Holders (each as hereinafter defined) from time to time of American Depositary Shares issued hereunder.
AMENDED AND RESTATED DEPOSIT AGREEMENT dated as of March 21, 2017, among THERAPIX BIOSCIENCES LTD., a company incorporated under the laws of the State of Israel (herein called the Company), THE BANK OF NEW YORK MELLON, a New York banking corporation (herein called the Depositary), and all Owners and Holders (each as hereinafter defined) from time to time of American Depositary Shares issued hereunder.
August 25th, 2014 · Common Contracts · 681 similar Vaccinogen Inc – Contract THIS WARRANT AND THE SHARES ISSUABLE UPON THE EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. EXCEPT AS OTHERWISE SET FORTH HEREIN OR IN A SUBSCRIPTION AGREEMENT DATED AS OF ___________, 2014, NEITHER THIS WARRANT NOR ANY OF SUCH SHARES MAY BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR SUCH SECURITIES UNDER SAID ACT OR, AN OPINION OF COUNSEL, IN FORM, SUBSTANCE AND SCOPE, CUSTOMARY FOR OPINIONS OF COUNSEL IN COMPARABLE TRANSACTIONS, THAT REGISTRATION IS NOT REQUIRED UNDER SUCH ACT OR UNLESS SOLD PURSUANT TO RULE 144 OR REGULATION S UNDER SUCH ACT. THE WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THE WARRANT MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT SECURED BY SUCH SECURITIES.
THIS WARRANT AND THE SHARES ISSUABLE UPON THE EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. EXCEPT AS OTHERWISE SET FORTH HEREIN OR IN A SUBSCRIPTION AGREEMENT DATED AS OF ___________, 2014, NEITHER THIS WARRANT NOR ANY OF SUCH SHARES MAY BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR SUCH SECURITIES UNDER SAID ACT OR, AN OPINION OF COUNSEL, IN FORM, SUBSTANCE AND SCOPE, CUSTOMARY FOR OPINIONS OF COUNSEL IN COMPARABLE TRANSACTIONS, THAT REGISTRATION IS NOT REQUIRED UNDER SUCH ACT OR UNLESS SOLD PURSUANT TO RULE 144 OR REGULATION S UNDER SUCH ACT. THE WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THE WARRANT MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT SECURED BY SUCH SECURITIES.
May 5th, 2022 · Common Contracts · 670 similar First Wave BioPharma, Inc. – Contract
April 18th, 2022 · Common Contracts · 627 similar Liquidia Corp – 9,803,922 Shares Liquidia Corporation UNDERWRITING AGREEMENT Introductory. Liquidia Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 9,803,922 shares of its common stock, par value $0.001 per share (the “Shares”). The 9,803,922 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 1,470,588 Shares as provided in Section 2. The additional 1,470,588 Shares to be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Shares.” BofA Securities, Inc. (“BofA”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriter
Introductory. Liquidia Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 9,803,922 shares of its common stock, par value $0.001 per share (the “Shares”). The 9,803,922 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 1,470,588 Shares as provided in Section 2. The additional 1,470,588 Shares to be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Shares.” BofA Securities, Inc. (“BofA”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriter
April 28th, 2022 · Common Contracts · 599 similar Deciphera Pharmaceuticals, Inc. – DECIPHERA PHARMACEUTICALS, INC. 5,251,239 shares of common stock, par value $0.01 per share and pre-funded warrants to purchase 9,748,761 shares of common stock Underwriting Agreement Deciphera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), (i) an aggregate of 5,251,239 shares of common stock, par value $0.01 per share (the “Common Stock”), of the Company (the “Underwritten Shares”) and (ii) pre-funded warrants to purchase an aggregate of 9,748,761 shares of Common Stock in a form to be mutually agreed by the Company and the Representatives (the “Warrants”) and, at the option of the Underwriters, up to an additional 2,250,000 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Warrants are herein referred to as the “Underwritten Securities.” The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The Shares and the Warrants are herein referred to as the “Securities.” The shares of Common Stock issuable upon exe
Deciphera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), (i) an aggregate of 5,251,239 shares of common stock, par value $0.01 per share (the “Common Stock”), of the Company (the “Underwritten Shares”) and (ii) pre-funded warrants to purchase an aggregate of 9,748,761 shares of Common Stock in a form to be mutually agreed by the Company and the Representatives (the “Warrants”) and, at the option of the Underwriters, up to an additional 2,250,000 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Warrants are herein referred to as the “Underwritten Securities.” The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The Shares and the Warrants are herein referred to as the “Securities.” The shares of Common Stock issuable upon exe
April 1st, 2022 · Common Contracts · 549 similar Propanc Biopharma, Inc. – SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of March 29, 2022, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with headquarters located at 302, 6 Butler Street, Camberwell, VIC 3124 Australia (the “Company”), and ONE44 CAPITAL LLC, a Nevada limited liability company, with its address at 1 East Liberty Street Suite 600, Reno, Nevada 89501 (the “Buyer”).
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of March 29, 2022, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with headquarters located at 302, 6 Butler Street, Camberwell, VIC 3124 Australia (the “Company”), and ONE44 CAPITAL LLC, a Nevada limited liability company, with its address at 1 East Liberty Street Suite 600, Reno, Nevada 89501 (the “Buyer”).
September 27th, 2021 · Common Contracts · 532 similar Ensysce Biosciences, Inc. – SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 24, 2021, between Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
This Securities Purchase Agreement (this “Agreement”) is dated as of September 24, 2021, between Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
August 7th, 2020 · Common Contracts · 523 similar Emergent BioSolutions Inc. – EMERGENT BIOSOLUTIONS INC. AND EACH OF THE GUARANTORS FROM TIME TO TIME PARTY HERETO 3.875% SENIOR UNSECURED NOTES DUE 2028 INDENTURE Dated as of August 7, 2020 U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE dated as of August 7, 2020 among Emergent BioSolutions Inc., a Delaware corporation (the “Company”), the Guarantors (as defined below) from time to time party hereto and U.S. Bank National Association, as trustee (the “Trustee”).
INDENTURE dated as of August 7, 2020 among Emergent BioSolutions Inc., a Delaware corporation (the “Company”), the Guarantors (as defined below) from time to time party hereto and U.S. Bank National Association, as trustee (the “Trustee”).
October 19th, 2020 · Common Contracts · 467 similar Endo International PLC – AGREEMENT AND PLAN OF MERGER BY AND AMONG ENDO INTERNATIONAL PLC, BETA ACQUISITION CORP. AND BIOSPECIFICS TECHNOLOGIES CORP. DATED AS OF OCTOBER 19, 2020 THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of October 19, 2020 by and among Endo International plc, a public limited company incorporated in Ireland (“Parent”), Beta Acquisition Corp., a Delaware corporation and a wholly-owned Subsidiary of Parent (“Merger Sub”), and BioSpecifics Technologies Corp., a Delaware corporation (the “Company”).
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of October 19, 2020 by and among Endo International plc, a public limited company incorporated in Ireland (“Parent”), Beta Acquisition Corp., a Delaware corporation and a wholly-owned Subsidiary of Parent (“Merger Sub”), and BioSpecifics Technologies Corp., a Delaware corporation (the “Company”).
April 2nd, 2010 · Common Contracts · 449 similar Med Gen Inc – REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of February 10, 2010, by and among Med Gen, Inc., a Nevada corporation with its headquarters located at 7280 W. Palmetto Park Road, Suite 306, Boca Raton, FL 33433 (the “Company”), and each of the undersigned (together with their respective affiliates and any assignee or transferee of all of their respective rights hereunder, the “Initial Investors”).
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of February 10, 2010, by and among Med Gen, Inc., a Nevada corporation with its headquarters located at 7280 W. Palmetto Park Road, Suite 306, Boca Raton, FL 33433 (the “Company”), and each of the undersigned (together with their respective affiliates and any assignee or transferee of all of their respective rights hereunder, the “Initial Investors”).
April 26th, 2021 · Common Contracts · 431 similar Vaccitech PLC – VACCITECH PLC AND THE BANK OF NEW YORK MELLON DEPOSIT AGREEMENT dated as of __________, 2021 among VACCITECH PLC, a company incorporated under the laws of England and Wales (herein called the Company), THE BANK OF NEW YORK MELLON, a New York banking corporation (herein called the Depositary), and all Owners and Holders (each as hereinafter defined) from time to time of American Depositary Shares issued hereunder.
DEPOSIT AGREEMENT dated as of __________, 2021 among VACCITECH PLC, a company incorporated under the laws of England and Wales (herein called the Company), THE BANK OF NEW YORK MELLON, a New York banking corporation (herein called the Depositary), and all Owners and Holders (each as hereinafter defined) from time to time of American Depositary Shares issued hereunder.
May 26th, 2020 · Common Contracts · 426 similar Viela Bio, Inc. – Viela Bio, Inc. Common Stock Underwriting Agreement Viela Bio, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom you are acting as Representatives, an aggregate of [•] shares (the “Firm Shares”) of common stock, par value $0.001 per share (“Stock”), of the Company. In addition, the stockholders of the Company named in Schedule II hereto (the “Selling Stockholders”) propose, subject to the terms and conditions stated in this Agreement, to sell, at the election of the Underwriters, up to [•] additional shares (the “Optional Shares”) of Stock (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
Viela Bio, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”), for whom you are acting as Representatives, an aggregate of [•] shares (the “Firm Shares”) of common stock, par value $0.001 per share (“Stock”), of the Company. In addition, the stockholders of the Company named in Schedule II hereto (the “Selling Stockholders”) propose, subject to the terms and conditions stated in this Agreement, to sell, at the election of the Underwriters, up to [•] additional shares (the “Optional Shares”) of Stock (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
November 1st, 2021 · Common Contracts · 419 similar IO Biotech, Inc. – •] Shares IO Biotech, Inc. COMMON STOCK (PAR VALUE [•]) UNDERWRITING AGREEMENT
April 14th, 2022 · Common Contracts · 417 similar Clene Inc. – CLENE INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of ___________________, 202___ Subordinated Debt Securities WHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and delivery of this Indenture to provide for the issuance of subordinated debt securities (hereinafter referred to as the “Securities”), in an unlimited aggregate principal amount to be issued from time to time in one or more series as in this Indenture provided, as registered Securities without coupons, to be authenticated by the certificate of the Trustee;
WHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and delivery of this Indenture to provide for the issuance of subordinated debt securities (hereinafter referred to as the “Securities”), in an unlimited aggregate principal amount to be issued from time to time in one or more series as in this Indenture provided, as registered Securities without coupons, to be authenticated by the certificate of the Trustee;
September 9th, 2019 · Common Contracts · 405 similar Neurotrope, Inc. – RIGHTS AGREEMENT Dated as of September 9, 2019 between NEUROTROPE, INC. and PHILADELPHIA STOCK TRANSFER, INC. as Rights Agent This Rights Agreement (this “Agreement”), dated as of September 9, 2019, is between Neurotrope, Inc., a Nevada corporation (the “Company”), and Philadelphia Stock Transfer, Inc., a Pennsylvania company, as rights agent (the “Rights Agent”).
This Rights Agreement (this “Agreement”), dated as of September 9, 2019, is between Neurotrope, Inc., a Nevada corporation (the “Company”), and Philadelphia Stock Transfer, Inc., a Pennsylvania company, as rights agent (the “Rights Agent”).
May 18th, 2022 · Common Contracts · 400 similar Propanc Biopharma, Inc. – SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of May 12, 2022, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with its address at 302, 6 Butler Street, Camberwell, VIC, 3124 Australia (the “Company”), and 1800 DIAGONAL LENDING LLC, a Virginia limited liability company, with its address at 1800 Diagonal Road, Suite 623, Alexandria, VA 22314 (the “Buyer”).
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of May 12, 2022, by and between PROPANC BIOPHARMA, INC., a Delaware corporation, with its address at 302, 6 Butler Street, Camberwell, VIC, 3124 Australia (the “Company”), and 1800 DIAGONAL LENDING LLC, a Virginia limited liability company, with its address at 1800 Diagonal Road, Suite 623, Alexandria, VA 22314 (the “Buyer”).
September 29th, 2021 · Common Contracts · 400 similar Catalent, Inc. – as Trustee 3.500% SENIOR NOTES DUE 2030 This INDENTURE, dated as of September 29, 2021, is among Catalent Pharma Solutions, Inc. (the “Issuer”), a Delaware corporation, the Guarantors (as defined herein) listed on the signature pages hereto and Deutsche Bank Trust Company Americas, a New York banking corporation, as trustee (the “Trustee”).
This INDENTURE, dated as of September 29, 2021, is among Catalent Pharma Solutions, Inc. (the “Issuer”), a Delaware corporation, the Guarantors (as defined herein) listed on the signature pages hereto and Deutsche Bank Trust Company Americas, a New York banking corporation, as trustee (the “Trustee”).
July 8th, 2020 · Common Contracts · 400 similar Alpine Immune Sciences, Inc. – ALPINE IMMUNE SCIENCES, INC. AS TRUSTEE TO INDENTURE DATED AS OF [●] DEBT SECURITIES INDENTURE, dated as of [●], between Alpine Immune Sciences, Inc., a corporation duly organized and existing under the laws of the State of Delaware (herein called the “Company”), having its principal executive office at 188 East Blaine Street, Suite 200, Seattle, Washington 98102, and [_________], as Trustee (herein called the “Trustee”).
INDENTURE, dated as of [●], between Alpine Immune Sciences, Inc., a corporation duly organized and existing under the laws of the State of Delaware (herein called the “Company”), having its principal executive office at 188 East Blaine Street, Suite 200, Seattle, Washington 98102, and [_________], as Trustee (herein called the “Trustee”).
May 13th, 2021 · Common Contracts · 399 similar Dynavax Technologies Corp – DYNAVAX TECHNOLOGIES CORPORATION AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of May 13, 2021 2.50% Convertible Senior Notes due 2026 INDENTURE dated as of May 13, 2021 between DYNAVAX TECHNOLOGIES CORPORATION, a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and U.S. BANK NATIONAL ASSOCIATION, a national banking association, as trustee (the “Trustee,” as more fully set forth in Section 1.01).
INDENTURE dated as of May 13, 2021 between DYNAVAX TECHNOLOGIES CORPORATION, a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and U.S. BANK NATIONAL ASSOCIATION, a national banking association, as trustee (the “Trustee,” as more fully set forth in Section 1.01).
March 10th, 2017 · Common Contracts · 385 similar Neurotrope, Inc. – FORM OF INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of ___________, 2017, by and between NEUROTROPE, INC., a Nevada corporation (the “Company”), and ________________ (“Indemnitee”).
THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of ___________, 2017, by and between NEUROTROPE, INC., a Nevada corporation (the “Company”), and ________________ (“Indemnitee”).